{"gene":"ALDH1A1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2003,"finding":"ALDH1A1 (Raldh1) functions as a retinaldehyde dehydrogenase in the second step of retinoic acid synthesis, acting downstream of alcohol dehydrogenase ADH1 to oxidize retinaldehyde to retinoic acid in adult mice. Raldh1-/- mice showed 72% reduction in serum RA levels and 2.5-fold accumulation of retinaldehyde after retinol dosing, establishing the enzymatic pathway position.","method":"Genetic knockout mouse model (Raldh1-/-), serum RA/retinaldehyde measurement, epistasis with Adh1-/- mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo genetic epistasis with quantitative metabolite measurement, replicated across two knockout lines","pmids":["12851412"],"is_preprint":false},{"year":2003,"finding":"ALDH1A1 (Raldh1) is expressed in the dorsal neural retina and provides retinoic acid signaling required for dorsal retina development; Raldh1-/- mice lose RARE-lacZ RA reporter activity in dorsal retina at E16.5, demonstrating its non-redundant role in late dorsal RA synthesis when Raldh3 is absent from dorsal retina.","method":"Targeted gene disruption, RARE-lacZ transgenic reporter, retrograde ganglion cell labeling, electroretinography","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — clean knockout with multiple orthogonal readouts in a single rigorous study","pmids":["12808103"],"is_preprint":false},{"year":2003,"finding":"Rabbit and human recombinant ALDH1A1 proteins efficiently oxidize lipid peroxidation aldehydes including hexanal (Km = 3.5 µM), 4-hydroxynonenal (Km = 2.1 µM), and malondialdehyde (Km = 14.0 µM), indicating a corneal cytoprotective function against UV-induced oxidative damage.","method":"Baculovirus expression and affinity purification of recombinant protein, in vitro enzymatic kinetic assay","journal":"DNA and cell biology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted recombinant enzyme with kinetic constants for multiple substrates","pmids":["12941160"],"is_preprint":false},{"year":2002,"finding":"ALDH1A1 possesses both dehydrogenase and esterase activities; the competitive irreversible inhibitor DIMATE acts via ALDH1A1 esterase activity to release methanethiol, which lowers mitochondrial glutathione and induces apoptosis in cells overexpressing BCL2. This identifies a mechanism by which ALDH1 enzymatic inhibition can overcome drug resistance.","method":"In vitro enzyme inhibition assay, ALDH1-transfected L1210 cells, DNA fragmentation apoptosis assay, intramitochondrial glutathione measurement","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay plus cell-based mechanistic follow-up, single study","pmids":["12234608"],"is_preprint":false},{"year":2011,"finding":"ALDH1A1 is a direct transcriptional target of EZH2 in epithelial ovarian cancer; EZH2 and H3K27Me3 bind the ALDH1A1 genomic locus, and EZH2 knockdown de-represses ALDH1A1 expression in a H3K27Me3-dependent manner, as validated by ChIP-seq and gene expression profiling.","method":"ChIP-seq for EZH2/H3K27Me3, EZH2 knockdown with gene expression microarray, ChIP validation","journal":"Cancer prevention research (Philadelphia, Pa.)","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP-seq plus functional validation by knockdown, multiple orthogonal methods","pmids":["22144423"],"is_preprint":false},{"year":2014,"finding":"ALDH1A1 in multiple myeloma generates the RXRα ligand 9-cis retinoic acid (not the RARα ligand ATRA), which activates RXRα to upregulate NEK2 kinase expression, which in turn increases drug-efflux pump activity (ABCB1) and promotes drug resistance. shRNA knockdown of NEK2 decreased drug efflux and resistance.","method":"Enforced ALDH1A1 expression in myeloma cells, shRNA knockdown of NEK2, mRNA/protein quantification, drug efflux assay, in vivo tumor formation","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (overexpression, knockdown, metabolite identification, drug efflux assay, in vivo) in single study","pmids":["25230277"],"is_preprint":false},{"year":2014,"finding":"β-Catenin directly regulates ALDH1A1 transcription in ovarian cancer spheroids; β-catenin co-immunoprecipitates with the ALDH1A1 promoter, and β-catenin knockdown decreases ALDH1A1 expression and disrupts spheroid formation.","method":"Co-immunoprecipitation with ALDH1A1 promoter, siRNA knockdown, spheroid formation assay, small-molecule ALDH1A1 inhibitor (A37)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP/co-IP of promoter, siRNA knockdown, pharmacological inhibition with concordant phenotypes","pmids":["24954508"],"is_preprint":false},{"year":2018,"finding":"DDB2 (DNA damage-binding protein 2) represses ALDH1A1 transcription by binding to the ALDH1A1 promoter, promoting H3K27me3 enrichment, and competing with the transcription factor C/EBPβ for promoter occupancy, thereby suppressing ovarian cancer cell dedifferentiation.","method":"ChIP assay, promoter binding competition assay, DDB2 knockdown/overexpression, H3K27me3 enrichment at ALDH1A1 promoter","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — ChIP with multiple orthogonal functional readouts, mechanistic promoter competition established","pmids":["29752431"],"is_preprint":false},{"year":2018,"finding":"Cdk5 phosphorylates ALDH1A1, which prevents its ubiquitylation and increases protein stability; Cdk5-mediated phosphorylation also alters ALDH1A1 from a tetrameric to a highly active monomeric state, increasing dehydrogenase activity. Under sustained oxidative stress, Cdk5 ultimately inactivates ALDH1A1.","method":"In vitro kinase assay, phosphorylation-site mutagenesis, ubiquitylation assay, native gel analysis of oligomeric state, dehydrogenase activity assay","journal":"Molecular neurobiology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus mutagenesis, oligomeric state analysis, and activity measurement","pmids":["29948941"],"is_preprint":false},{"year":2020,"finding":"ARID1A recruits HDAC1 to the ALDH1A1 promoter, decreasing histone H3K27 acetylation and suppressing ALDH1A1 transcription. ARID1A knockout via CRISPR/Cas9 increases H3K27 acetylation at the ALDH1A1 promoter and markedly upregulates ALDH1A1 expression and ALDH enzyme activity.","method":"CRISPR/Cas9 knockout, ChIP assay for ARID1A and HDAC1 at ALDH1A1 promoter, H3K27 acetylation ChIP, microarray gene expression","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO with ChIP-based mechanistic validation of promoter regulation","pmids":["31665232"],"is_preprint":false},{"year":2019,"finding":"ALDH1A1 contributes to PARP inhibitor resistance in BRCA2-deficient ovarian cancer cells by enhancing microhomology-mediated end joining (MMEJ) DNA repair. ALDH1A1 knockdown reduced MMEJ activity as measured by an intrachromosomal MMEJ reporter, and selective ALDH1A1 inhibitor NCT-501 synergized with olaparib in vitro and in vivo.","method":"siRNA knockdown, intrachromosomal MMEJ reporter assay, selective ALDH1A1 inhibitor (NCT-501), xenograft model","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — functional MMEJ reporter plus pharmacological and genetic inhibition with in vivo validation","pmids":["31534014"],"is_preprint":false},{"year":2019,"finding":"ALDH1A1 inhibition with CM37 increases intracellular ROS accumulation, which leads to DNA damage (γH2AX induction) and upregulation of DNA damage response genes (NEIL3), reducing ovarian cancer cell viability in ALDH+ cancer stem cell populations.","method":"ALDH1A1 small-molecule inhibitor CM37, siRNA knockdown, γH2AX immunofluorescence, ROS measurement, in vivo limiting dilution assay","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic inhibition with mechanistic ROS/DNA damage readout, single study","pmids":["30965686"],"is_preprint":false},{"year":2021,"finding":"ALDH1A1 enzymatic activity decreases intracellular pH in breast cancer tumor-initiating cells, promoting phosphorylation of TAK1, activating NF-κB signaling, and increasing GM-CSF secretion, which drives expansion of myeloid-derived suppressor cells and creates an immunosuppressive tumor microenvironment.","method":"ALDH1A1 enzymatic inhibitor (disulfiram), siRNA/shRNA knockdown, intracellular pH measurement, TAK1 phosphorylation assay, GM-CSF ELISA, MDSC flow cytometry, syngeneic tumor models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods linking enzymatic activity to intracellular pH, TAK1/NFκB signaling, and immune phenotype in vitro and in vivo","pmids":["34580061"],"is_preprint":false},{"year":2022,"finding":"S100A9 upregulates ALDH1A1 expression and activates the downstream retinoic acid (RA) signaling pathway in osimertinib-refractory EGFR-mutant lung cancer cells; genetic repression of S100A9, ALDH1A1, or RA receptors (RAR) dramatically reduces brain metastasis.","method":"Genetic knockdown of S100A9/ALDH1A1/RARs, pan-RAR antagonist treatment, brain metastasis mouse models","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic perturbations with consistent in vivo phenotypes establishing pathway order","pmids":["35078784"],"is_preprint":false},{"year":2017,"finding":"TAZ transcriptional co-activator induces ALDH1A1 transcription by activating the ALDH1A1 promoter through interaction with the TEAD transcription factor. CRISPR knockout or pharmacological inhibition of ALDH1A1 suppresses TAZ-induced lung cancer stem cell and tumorigenic phenotypes.","method":"RNA-seq, ALDH1A1 promoter-luciferase reporter assay, TAZ-TEAD interaction assay, CRISPR knockout, ALDH1A1 inhibitor (A37), in vivo tumor formation","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — promoter assay, CRISPR KO and pharmacological inhibition with in vivo tumor readout","pmids":["28415606"],"is_preprint":false},{"year":2018,"finding":"STAT3 is a transcriptional activator of ALDH1 isozymes; TESC activates IGF1Rβ by direct recruitment of c-Src to the IGF1Rβ complex, leading to STAT3 activation that upregulates ALDH1 expression to maintain cancer stem cell properties and radioresistance.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, co-immunoprecipitation of c-Src/IGF1Rβ, TESC knockdown, IGF1R inhibitor (AG1024)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and luciferase assay plus co-IP and pharmacological inhibition, single study","pmids":["30013043"],"is_preprint":false},{"year":2022,"finding":"YAP (Yes-associated protein) transcriptionally activates ALDH1A1; ectopic expression of human ALDH1A1 in Yap1 hepatocyte-specific knockout mice reduces hepatic necrosis, oxidative stress, ECM remodeling, and inflammation during alcohol/CCl4-induced liver damage, demonstrating a protective detoxification role downstream of YAP.","method":"AAV8-Cre-mediated hepatocyte-specific Yap1 knockout, whole-genome transcriptomics, ectopic ALDH1A1 expression rescue experiment, hyperactive YAP mutant transactivation assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with rescue by ectopic ALDH1A1, transcriptomic confirmation, single study","pmids":["35218575"],"is_preprint":false},{"year":2021,"finding":"ALDH1A1 and ALDH1A2 together are required for RA synthesis in Sertoli cells to initiate spermatogonial differentiation; global double knockout of Aldh1a1 and Aldh1a2 blocks spermatogenesis completely, and remaining Aldh1a3 activity cannot compensate. Cell-specific deletion showed that Sertoli cell RA synthesis is required but germ cell RA synthesis is not.","method":"Global gene deletion (Aldh1a1 KO mouse), Cre-loxP conditional Aldh1a2 deletion in Sertoli cells and germ cells, histological analysis of spermatogenesis","journal":"Frontiers in endocrinology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic knockouts with cell-type-specific dissection of function, multiple combinations tested","pmids":["35574006"],"is_preprint":false},{"year":2018,"finding":"5-Nitrofuran nifuroxazide is selectively bio-activated by ALDH1A1/1A3 enzymes; it both oxidizes ALDH1 and is converted to cytotoxic metabolites in a two-hit pro-drug mechanism. ALDH1A3 loss-of-function mutations confer resistance to nifuroxazide, confirming that ALDH1 enzymatic activity is required for drug activation.","method":"In vitro ALDH1A1 oxidation assay, ALDH1A3 loss-of-function mutagenesis, cytotoxicity assays, in vivo tumor xenograft","journal":"Cell chemical biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay plus mutagenesis confirming enzyme-dependent drug activation","pmids":["30293938"],"is_preprint":false},{"year":2021,"finding":"Omeprazole, after photoactivation, binds in the active site of ALDH1A1 and activates it, protecting eukaryotic cells from oxidative stress-induced lipid aldehyde accumulation. Disulfiram (ALDH inhibitor) blocks this protection, confirming ALDH1A1-mediated cell defense.","method":"ALDH total activity assay in cell suspensions, lipid aldehyde quantification, cell viability assay, disulfiram inhibition control, mitochondrial function assessment","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological activation and inhibition with multiple functional readouts, single study","pmids":["33400378"],"is_preprint":false},{"year":2016,"finding":"ALDH1A1 induces resistance to CHOP chemotherapy in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway; ALDH1A1 overexpression upregulates p-STAT3, and JAK2/STAT3 pathway inhibitor WP1066 negates the resistance conferred by ALDH1A1 overexpression.","method":"ALDH1A1 overexpression, shRNA knockdown, JAK2/STAT3 inhibitor (WP1066), caspase activity assay, western blot for p-STAT3","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression, knockdown, and pharmacological rescue identifying JAK2/STAT3 as mediator, single study","pmids":["27621650"],"is_preprint":false},{"year":2022,"finding":"EHMT1 methyltransferase does not directly bind the ALDH1A1 promoter but activates it by stabilizing C/EBPβ, a known transcriptional regulator of ALDH1A1 expression. EHMT1 depletion reduces ALDH1A1 expression, decreasing tumorsphere formation and tumor progression in rhabdomyosarcoma.","method":"RNA sequencing, EHMT1 knockdown, ChIP assay, C/EBPβ stabilization assay, ALDH1A1 inhibitor, tumorsphere assay, mouse xenograft","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-based mechanism with functional rescue, single study","pmids":["34897678"],"is_preprint":false},{"year":2022,"finding":"Loss of PBRM1 (PBAF SWI/SNF subunit) results in de novo H3K4me3 gains at the ALDH1A1 promoter, activating ALDH1A1 transcription. ARID2 (another PBAF subunit) remains bound after PBRM1 loss and is essential for ALDH1A1 upregulation, while BRG1 is dispensable. Increased ALDH1A1 enhances tumorigenic potential of ccRCC cells.","method":"RNA-seq, H3K4me3 ChIP-seq, ATAC-seq, PBRM1/ARID2 knockdown, BRG1 knockdown, ccRCC cell tumorigenicity assay","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1-2 — integrated multi-omic epigenomic approach with multiple genetic perturbations identifying specific chromatin mechanism","pmids":["35412614"],"is_preprint":false},{"year":2023,"finding":"ALDH1A1 is modified by 2-hydroxyisobutyrylation at lysine-260 (K260hib); higher K260hib modification promotes ALDH1A1 protein degradation through chaperone-mediated autophagy (CMA) and is regulated by HDAC2/3. Lower K260hib (as seen in bladder cancer) stabilizes ALDH1A1 protein and enhances its activity.","method":"Protein modification omics, K260hib-specific mutagenesis, HDAC2/3 inhibition assays, CMA pathway analysis, bladder cancer cell functional assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — novel PTM identified by omics with mutagenesis and degradation pathway confirmation, single study","pmids":["37867947"],"is_preprint":false},{"year":2024,"finding":"KRAS inhibitors dephosphorylate GTF2I at S784 via ERK, blocking its nuclear translocation and upregulating ALDH1A1 expression. Elevated ALDH1A1 suppresses KRAS inhibitor efficacy by detoxifying lipid aldehydes, boosting NADH and RA synthesis, activating RARA function and the CREB1/GPX4 pathway, stimulating lipid droplet production in a pH-dependent manner, and thereby counteracting ferroptosis.","method":"ALDH1A1 knockout/inhibitor, GTF2I phosphorylation analysis, CREB1/GPX4 pathway analysis, lipid droplet quantification, patient-derived organoids, xenograft models","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanisms tested with genetic KO and PDO models, single study","pmids":["39317105"],"is_preprint":false},{"year":2021,"finding":"In the ventral tegmental area, Aldh1a1 neurons are a subtype of GABAergic inhibitory interneurons that synthesize GABA using ALDH1A1 rather than GAD, project inhibitory synapses onto excitatory glutamate neurons in the intermediate lateral septum (EGNIS), and receive inputs from layer 5b medial prefrontal cortex pyramidal neurons. L5PN→Aldh1a1 synaptic transmission undergoes LTP, and dysfunction of this circuit produces impulsive behaviors.","method":"Aldh1a1-CRE knock-in mice, anterograde/retrograde synaptic tracing, optogenetic circuit manipulation, LTP electrophysiology, genetic silencing, exogenous Aldh1a1 rescue in AD mice","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 — circuit mapping with multiple genetic and electrophysiological methods plus rescue experiment","pmids":["34702328"],"is_preprint":false},{"year":2024,"finding":"ALDH1A1 interacts with the transcription factor ZBTB7B; ALDH1A1 promotes ZBTB7B SUMOylation to stabilize its activity, and ZBTB7B binds the LDHA promoter to regulate glycolysis. ALDH1A1 deficiency reduces ZBTB7B-dependent LDHA expression, decreasing tumor glycolysis and reducing immune evasion.","method":"RNA-seq, luciferase reporter assay, ChIP-qPCR for ZBTB7B at LDHA promoter, Co-IP, SUMOylation assay, xenograft in immune-normal mice, flow cytometry","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, co-IP, and luciferase assay establishing pathway, single study","pmids":["39107297"],"is_preprint":false},{"year":2025,"finding":"Labile hepatic copper (Cu) activity increases with age in mice and inversely correlates with ALDH1A1 activity. Treatment with copper chelator ATN-224 restores Cu homeostasis and preserves ALDH1A1 protective activity, establishing a direct mechanistic link between Cu dysregulation and ALDH1A1 functional decline in liver aging.","method":"Activity-based Cu(I) imaging probes, photoacoustic glutathione imaging, longitudinal aging mouse study, Cu chelator (ATN-224) treatment, ALDH1A1 activity assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — novel activity-based probes with functional rescue by chelation, single study","pmids":["39979263"],"is_preprint":false},{"year":2025,"finding":"The E3 ubiquitin ligase FBXL12 ubiquitinates ALDH1A1, targeting it for degradation. Sorcin normally sequesters PAX5 in the cytoplasm; disruption of the sorcin-PAX5 interaction (e.g., by celastrol binding Cys194 of sorcin) allows PAX5 nuclear translocation, which induces FBXL12 expression, increases ALDH1A1 ubiquitylation, depletes ALDH1A1 protein, and promotes ferroptosis in pancreatic cancer cells.","method":"Co-IP, ChIP assay, luciferase reporter, proteomics, FBXL12 overexpression/knockdown, ubiquitylation assay, celastrol docking and functional studies","journal":"Journal of hematology & oncology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical methods identifying ubiquitin writer FBXL12 and upstream PAX5 regulation, single study","pmids":["40055736"],"is_preprint":false},{"year":2024,"finding":"ALDH1A1 drives prostate cancer metastasis and radioresistance through interplay with androgen receptor (AR) and retinoid receptor (RAR) transcriptional programs; RNAseq and ChIP analyses identify PLK3 as a transcriptional target oppositely regulated by ALDH1A1 (activating) and ALDH1A3 (repressing) in RAR/AR-dependent manner, contributing to proliferation, migration, DNA repair, and radioresistance.","method":"ALDH1A1/ALDH1A3 genetic silencing, RNAseq, ChIP, zebrafish and murine xenograft models, comparative IHC of clinical specimens","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and RNAseq with in vivo validation, single study identifying transcriptional mechanism","pmids":["38169509"],"is_preprint":false},{"year":2024,"finding":"Melanoma cells overexpressing ALDH1A1 resist BRAF/MEK inhibitors (vemurafenib/trametinib) through activation of PI3K/AKT signaling rather than the MAPK axis; pharmacological inhibition of ALDH1A1 activity downregulates AKT phosphorylation and partially restores drug sensitivity, while PI3K/AKT inhibition also rescues sensitivity.","method":"ALDH1A1 overexpression, ALDH1A1 pharmacological inhibitor, PI3K/AKT inhibitor, western blot for p-AKT, drug sensitivity assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibitor combined with pathway inhibitor rescue establishing PI3K/AKT as mediator, single study","pmids":["38701866"],"is_preprint":false},{"year":2022,"finding":"ALDH1A1 inhibition with compound 974 suppresses platinum-induced cellular senescence and the senescence-associated secretory phenotype (SASP) in ovarian cancer stem cells, as demonstrated by transcriptomic sequencing and functional senescence assays, linking ALDH1A1 to regulation of chemotherapy-induced senescence.","method":"ALDH1A1 inhibitor (compound 974), transcriptomic RNA sequencing, functional senescence assays, in vivo limiting dilution assay","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition with transcriptomic and functional confirmation, single study","pmids":["35884498"],"is_preprint":false}],"current_model":"ALDH1A1 is a cytoplasmic NAD+-dependent aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid (acting downstream of ADH1 in retinol metabolism) and detoxifies lipid peroxidation aldehydes; its transcription is regulated by multiple epigenetic mechanisms (EZH2/H3K27me3, ARID1A/HDAC1, PBRM1/ARID2, DDB2/C/EBPβ, and activators including β-catenin, TAZ-TEAD, STAT3, and YAP), its protein stability is controlled by Cdk5 phosphorylation at a site that blocks ubiquitylation and by K260 2-hydroxyisobutyrylation-triggered CMA degradation via FBXL12, and its enzymatic activity drives diverse downstream pathways including 9-cis-RA/RXRα/NEK2-mediated drug efflux, intracellular pH reduction/TAK1/NFκB/GM-CSF-mediated immunosuppression, MMEJ-dependent DNA repair resistance, PI3K/AKT activation, ZBTB7B/LDHA glycolysis regulation, and ferroptosis suppression via CREB1/GPX4, while in GABAergic neurons of the VTA it functions as a GABA-synthetic enzyme whose activity is required for circuit-level control of impulse behavior."},"narrative":{"teleology":[{"year":2003,"claim":"ALDH1A1's biochemical identity as a retinaldehyde dehydrogenase and lipid aldehyde detoxifier was established, defining its dual enzymatic substrate repertoire and placing it in the retinol→retinaldehyde→retinoic acid pathway downstream of ADH1.","evidence":"Raldh1⁻/⁻ knockout mice with serum RA/retinaldehyde quantification and epistasis with Adh1⁻/⁻; recombinant enzyme kinetics for hexanal, 4-HNE, and MDA; RARE-lacZ reporter in dorsal retina of Raldh1⁻/⁻ mice","pmids":["12851412","12941160","12808103"],"confidence":"High","gaps":["Crystal structure-based substrate selectivity determinants not resolved","Relative contribution of ALDH1A1 vs ALDH1A2/1A3 to systemic RA not fully quantified","Retinaldehyde vs lipid aldehyde preference in different tissues not systematically compared"]},{"year":2011,"claim":"The first transcriptional repression mechanism was identified: EZH2 deposits H3K27me3 at the ALDH1A1 locus to silence it, revealing that ALDH1A1 expression is under Polycomb-mediated epigenetic control.","evidence":"ChIP-seq for EZH2 and H3K27me3 at ALDH1A1 locus, EZH2 knockdown de-repression in ovarian cancer cells","pmids":["22144423"],"confidence":"High","gaps":["Whether EZH2-mediated repression operates in non-cancer tissues unknown","Specific PRC2 recruitment mechanism to ALDH1A1 locus not defined"]},{"year":2014,"claim":"The downstream signaling output of ALDH1A1's RA product was delineated: 9-cis-RA activates RXRα to upregulate NEK2, which increases ABCB1 drug-efflux activity, establishing the first complete enzymatic product→receptor→effector pathway for ALDH1A1-mediated drug resistance.","evidence":"Enforced ALDH1A1 expression in myeloma cells, NEK2 shRNA, drug efflux assay, in vivo tumor model","pmids":["25230277"],"confidence":"High","gaps":["Whether all-trans-RA contributes through RAR-dependent pathways in this context not excluded","NEK2 regulation of ABCB1 mechanism not fully resolved"]},{"year":2014,"claim":"β-catenin was identified as a direct transcriptional activator at the ALDH1A1 promoter, linking Wnt signaling to ALDH1A1 expression and cancer stemness.","evidence":"ChIP/co-IP of β-catenin at ALDH1A1 promoter, siRNA knockdown, spheroid formation assay in ovarian cancer","pmids":["24954508"],"confidence":"High","gaps":["TCF/LEF binding site identity at ALDH1A1 promoter not mapped","Interplay between β-catenin activation and EZH2 repression at the same locus not tested"]},{"year":2017,"claim":"TAZ-TEAD was established as another transcriptional activator of ALDH1A1, expanding the set of oncogenic inputs that converge on ALDH1A1 transcription to include Hippo pathway effectors.","evidence":"ALDH1A1 promoter-luciferase, TAZ-TEAD interaction assay, CRISPR KO of ALDH1A1, ALDH1A1 inhibitor A37, in vivo tumor formation","pmids":["28415606"],"confidence":"High","gaps":["TEAD binding elements in ALDH1A1 promoter not mapped at base-pair resolution","Relative contribution of TAZ vs YAP at this promoter unclear"]},{"year":2018,"claim":"Post-translational regulation of ALDH1A1 was resolved: Cdk5 phosphorylation prevents ubiquitylation and stabilizes ALDH1A1 protein while converting it from an inactive tetramer to a highly active monomer, establishing the first kinase-dependent control of ALDH1A1 enzymatic output.","evidence":"In vitro kinase assay, phosphosite mutagenesis, ubiquitylation assay, native gel oligomeric state analysis, dehydrogenase activity measurement","pmids":["29948941"],"confidence":"High","gaps":["Phosphorylation site identity not fully mapped across all Cdk5 sites","Identity of the E3 ubiquitin ligase counteracted by Cdk5 phosphorylation was unknown at that time"]},{"year":2018,"claim":"Additional chromatin-level repression mechanisms were defined: DDB2 competes with C/EBPβ for ALDH1A1 promoter occupancy and promotes H3K27me3, while ARID1A recruits HDAC1 to reduce H3K27 acetylation, revealing that multiple SWI/SNF and DNA-damage factors independently silence ALDH1A1.","evidence":"ChIP for DDB2, C/EBPβ competition, H3K27me3 enrichment; CRISPR KO of ARID1A with HDAC1 ChIP at ALDH1A1 promoter","pmids":["29752431","31665232"],"confidence":"High","gaps":["Hierarchical relationship among EZH2, DDB2, and ARID1A repression at ALDH1A1 not dissected","Whether these mechanisms operate simultaneously or context-specifically unknown"]},{"year":2019,"claim":"A non-canonical function was uncovered: ALDH1A1 enhances microhomology-mediated end joining (MMEJ) DNA repair, contributing to PARP inhibitor resistance in BRCA2-deficient cells—the first link between ALDH1A1 and a specific DNA repair pathway.","evidence":"siRNA knockdown, intrachromosomal MMEJ reporter assay, selective ALDH1A1 inhibitor NCT-501, xenograft model","pmids":["31534014"],"confidence":"High","gaps":["Biochemical mechanism by which ALDH1A1 promotes MMEJ is unknown—whether via RA signaling or direct protein interaction unresolved","Whether this extends to other alternative end-joining pathways not tested"]},{"year":2021,"claim":"ALDH1A1 enzymatic activity was shown to lower intracellular pH, triggering TAK1 phosphorylation, NF-κB activation, and GM-CSF secretion that expands myeloid-derived suppressor cells, establishing a metabolite-to-immune-evasion signaling axis.","evidence":"Disulfiram inhibition and siRNA/shRNA knockdown, intracellular pH measurement, TAK1 phosphorylation, GM-CSF ELISA, MDSC flow cytometry, syngeneic tumor models","pmids":["34580061"],"confidence":"High","gaps":["Which ALDH1A1-generated metabolite lowers pH not identified","Whether this pH-dependent mechanism operates in non-breast-cancer contexts unknown"]},{"year":2021,"claim":"In the brain, ALDH1A1 was identified as a GABA-synthetic enzyme in VTA GABAergic interneurons; these Aldh1a1⁺ neurons project to the intermediate lateral septum and receive mPFC layer 5b input, forming a circuit whose dysfunction produces impulsive behavior.","evidence":"Aldh1a1-CRE knock-in mice, anterograde/retrograde tracing, optogenetic manipulation, LTP electrophysiology, genetic silencing and rescue in AD mice","pmids":["34702328"],"confidence":"High","gaps":["Whether ALDH1A1-derived GABA synthesis is quantitatively significant vs GAD-mediated synthesis not measured","Mechanism of GABA synthesis by ALDH1A1 (substrate identity) not biochemically reconstituted"]},{"year":2021,"claim":"Cooperative RA synthesis by ALDH1A1 and ALDH1A2 in Sertoli cells was shown to be essential for spermatogonial differentiation; double knockout blocked spermatogenesis completely, establishing tissue-specific non-redundancy among ALDH1A isoforms.","evidence":"Aldh1a1 KO combined with Cre-loxP conditional Aldh1a2 deletion in Sertoli cells vs germ cells, histological analysis","pmids":["35574006"],"confidence":"High","gaps":["Relative RA contribution of ALDH1A1 vs ALDH1A2 in Sertoli cells not quantified","Downstream RA target genes in spermatogonial differentiation not identified"]},{"year":2022,"claim":"PBAF SWI/SNF chromatin remodeling was linked to ALDH1A1: PBRM1 loss causes de novo H3K4me3 at the ALDH1A1 promoter, and residual ARID2 is required for this activation, distinguishing PBAF-dependent regulation from canonical BRG1-dependent remodeling.","evidence":"RNA-seq, H3K4me3 ChIP-seq, ATAC-seq, PBRM1/ARID2/BRG1 knockdown in ccRCC cells","pmids":["35412614"],"confidence":"High","gaps":["How ARID2 activates ALDH1A1 in the absence of PBRM1 mechanistically unclear","Whether this applies outside ccRCC not tested"]},{"year":2023,"claim":"A novel PTM-degradation axis was identified: K260 2-hydroxyisobutyrylation (regulated by HDAC2/3) triggers ALDH1A1 degradation via chaperone-mediated autophagy, providing a non-ubiquitin mechanism for ALDH1A1 protein turnover.","evidence":"K260hib-specific mutagenesis, HDAC2/3 inhibition, CMA pathway analysis in bladder cancer cells","pmids":["37867947"],"confidence":"Medium","gaps":["The CMA receptor (LAMP2A) interaction with K260hib-modified ALDH1A1 not directly demonstrated","Writer enzyme for K260hib not identified","Single study awaiting independent replication"]},{"year":2024,"claim":"ALDH1A1's role in ferroptosis resistance was mechanistically dissected: ALDH1A1 detoxifies lipid aldehydes, generates NADH and RA, activates RARA and the CREB1/GPX4 axis, and promotes lipid droplet formation, collectively counteracting ferroptosis induced by KRAS inhibitors.","evidence":"ALDH1A1 knockout/inhibitor, GTF2I phosphorylation analysis, CREB1/GPX4 pathway assays, lipid droplet quantification, PDOs and xenografts","pmids":["39317105"],"confidence":"Medium","gaps":["Whether ferroptosis suppression is RA-dependent or lipid-aldehyde-clearance-dependent not fully resolved","Single study with complex multi-pathway model"]},{"year":2025,"claim":"The E3 ubiquitin ligase FBXL12 was identified as the specific ubiquitin writer for ALDH1A1 degradation, regulated upstream by sorcin-PAX5 cytoplasmic sequestration; disruption of this axis depletes ALDH1A1 and promotes ferroptosis.","evidence":"Co-IP, ChIP, luciferase reporter, FBXL12 overexpression/knockdown, ubiquitylation assay, celastrol functional studies in pancreatic cancer","pmids":["40055736"],"confidence":"Medium","gaps":["Whether FBXL12 is the same ligase antagonized by Cdk5 phosphorylation not tested","Sorcin-PAX5-FBXL12 axis validated only in pancreatic cancer","Celastrol target specificity beyond sorcin Cys194 not fully excluded"]},{"year":null,"claim":"Key open questions remain: the biochemical mechanism by which ALDH1A1 promotes MMEJ DNA repair, the identity of the metabolite(s) responsible for intracellular pH reduction, how multiple chromatin-regulatory inputs at the ALDH1A1 promoter are hierarchically integrated, and whether ALDH1A1's GABA-synthetic activity in VTA neurons proceeds through a defined substrate.","evidence":"","pmids":[],"confidence":"Low","gaps":["MMEJ promotion mechanism (RA-dependent vs direct) unresolved","pH-lowering metabolite identity unknown","Integration of EZH2/ARID1A/DDB2/PBRM1 chromatin regulation hierarchy at ALDH1A1 not tested","GABA synthesis substrate and kinetics not biochemically reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2,8,18,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,5,24]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,7,9,14,22]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,7,9,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,12,13,20,30]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,23,28]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,26]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[24,28]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[25]}],"complexes":[],"partners":["CDK5","FBXL12","ZBTB7B","EZH2","ARID1A","DDB2","ARID2"],"other_free_text":[]},"mechanistic_narrative":"ALDH1A1 is a cytoplasmic NAD⁺-dependent aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid and detoxifies lipid peroxidation-derived aldehydes, thereby serving as a central node linking retinoid signaling, redox homeostasis, and cellular differentiation. As the principal retinaldehyde dehydrogenase acting downstream of ADH1, ALDH1A1 generates retinoic acid species including 9-cis-RA that activate RAR/RXRα transcriptional programs, driving processes as diverse as dorsal retinal patterning, spermatogonial differentiation, drug-efflux pump upregulation via RXRα/NEK2, and ferroptosis resistance through CREB1/GPX4 [PMID:12851412, PMID:12808103, PMID:25230277, PMID:35574006, PMID:39317105]. Its transcription is regulated by multiple chromatin remodeling and signaling axes—repressed by EZH2/H3K27me3, ARID1A/HDAC1, DDB2/C/EBPβ competition, and PBRM1-containing PBAF, and activated by β-catenin, TAZ-TEAD, STAT3, and YAP—while protein stability is controlled by Cdk5 phosphorylation that blocks ubiquitylation and by FBXL12-mediated ubiquitin-dependent degradation and K260 2-hydroxyisobutyrylation-triggered chaperone-mediated autophagy [PMID:22144423, PMID:31665232, PMID:29752431, PMID:35412614, PMID:29948941, PMID:40055736, PMID:37867947]. Beyond canonical aldehyde metabolism, ALDH1A1 enzymatic activity lowers intracellular pH to activate TAK1/NF-κB/GM-CSF immunosuppressive signaling, promotes MMEJ-dependent DNA repair, interacts with ZBTB7B to regulate glycolysis via LDHA, and functions as a GABA-synthetic enzyme in VTA GABAergic neurons where it controls inhibitory circuit-level regulation of impulsive behavior [PMID:34580061, PMID:31534014, PMID:39107297, PMID:34702328]."},"prefetch_data":{"uniprot":{"accession":"P00352","full_name":"Aldehyde dehydrogenase 1A1","aliases":["3-deoxyglucosone dehydrogenase","ALDH-E1","ALHDII","Aldehyde dehydrogenase family 1 member A1","Aldehyde dehydrogenase, cytosolic","Retinal dehydrogenase 1","RALDH 1","RalDH1"],"length_aa":501,"mass_kda":54.9,"function":"Cytosolic dehydrogenase that catalyzes the irreversible oxidation of a wide range of aldehydes to their corresponding carboxylic acid (PubMed:12941160, PubMed:15623782, PubMed:17175089, PubMed:19296407, PubMed:25450233, PubMed:26373694). Functions downstream of retinol dehydrogenases and catalyzes the oxidation of retinaldehyde into retinoic acid, the second step in the oxidation of retinol/vitamin A into retinoic acid (By similarity). This pathway is crucial to control the levels of retinol and retinoic acid, two important molecules which excess can be teratogenic and cytotoxic (By similarity). Also oxidizes aldehydes resulting from lipid peroxidation like (E)-4-hydroxynon-2-enal/HNE, malonaldehyde and hexanal that form protein adducts and are highly cytotoxic. By participating for instance to the clearance of (E)-4-hydroxynon-2-enal/HNE in the lens epithelium prevents the formation of HNE-protein adducts and lens opacification (PubMed:12941160, PubMed:15623782, PubMed:19296407). Also functions downstream of fructosamine-3-kinase in the fructosamine degradation pathway by catalyzing the oxidation of 3-deoxyglucosone, the carbohydrate product of fructosamine 3-phosphate decomposition, which is itself a potent glycating agent that may react with lysine and arginine side-chains of proteins (PubMed:17175089). Also has an aminobutyraldehyde dehydrogenase activity and is probably part of an alternative pathway for the biosynthesis of GABA/4-aminobutanoate in midbrain, thereby playing a role in GABAergic synaptic transmission (By similarity)","subcellular_location":"Cytoplasm, cytosol; Cell projection, axon","url":"https://www.uniprot.org/uniprotkb/P00352/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALDH1A1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PI4K2A","stoichiometry":10.0},{"gene":"CHN1","stoichiometry":0.2},{"gene":"INPPL1","stoichiometry":0.2},{"gene":"PIP5K1A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ALDH1A1","total_profiled":1310},"omim":[{"mim_id":"606145","title":"SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 10; SLC2A10","url":"https://www.omim.org/entry/606145"},{"mim_id":"600502","title":"IMMUNOGLOBULIN MU-BINDING PROTEIN 2; IGHMBP2","url":"https://www.omim.org/entry/600502"},{"mim_id":"266600","title":"INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 1; IBD1","url":"https://www.omim.org/entry/266600"},{"mim_id":"208050","title":"ARTERIAL TORTUOSITY SYNDROME; ATORS","url":"https://www.omim.org/entry/208050"},{"mim_id":"103780","title":"ALCOHOL DEPENDENCE","url":"https://www.omim.org/entry/103780"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":1403.3}],"url":"https://www.proteinatlas.org/search/ALDH1A1"},"hgnc":{"alias_symbol":["RALDH1"],"prev_symbol":["PUMB1","ALDH1"]},"alphafold":{"accession":"P00352","domains":[{"cath_id":"3.40.605.10","chopping":"22-270_472-488","consensus_level":"high","plddt":98.8002,"start":22,"end":488},{"cath_id":"3.40.309.10","chopping":"273-453","consensus_level":"high","plddt":98.6974,"start":273,"end":453}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00352","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00352-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00352-F1-predicted_aligned_error_v6.png","plddt_mean":97.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALDH1A1","jax_strain_url":"https://www.jax.org/strain/search?query=ALDH1A1"},"sequence":{"accession":"P00352","fasta_url":"https://rest.uniprot.org/uniprotkb/P00352.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00352/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00352"}},"corpus_meta":[{"pmid":"18573038","id":"PMC_18573038","title":"ALDH1 as a functional marker of cancer stem and progenitor cells.","date":"2009","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/18573038","citation_count":262,"is_preprint":false},{"pmid":"12808103","id":"PMC_12808103","title":"Targeted disruption of Aldh1a1 (Raldh1) provides evidence for a complex mechanism of retinoic acid synthesis in the developing retina.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12808103","citation_count":189,"is_preprint":false},{"pmid":"24954508","id":"PMC_24954508","title":"β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24954508","citation_count":154,"is_preprint":false},{"pmid":"22222226","id":"PMC_22222226","title":"ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22222226","citation_count":143,"is_preprint":false},{"pmid":"34580061","id":"PMC_34580061","title":"ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34580061","citation_count":133,"is_preprint":false},{"pmid":"12851412","id":"PMC_12851412","title":"Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12851412","citation_count":123,"is_preprint":false},{"pmid":"21062915","id":"PMC_21062915","title":"Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21062915","citation_count":112,"is_preprint":false},{"pmid":"20010944","id":"PMC_20010944","title":"Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20010944","citation_count":82,"is_preprint":false},{"pmid":"28937653","id":"PMC_28937653","title":"Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28937653","citation_count":78,"is_preprint":false},{"pmid":"21231983","id":"PMC_21231983","title":"Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21231983","citation_count":73,"is_preprint":false},{"pmid":"35814382","id":"PMC_35814382","title":"ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35814382","citation_count":64,"is_preprint":false},{"pmid":"25230277","id":"PMC_25230277","title":"NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25230277","citation_count":62,"is_preprint":false},{"pmid":"25742746","id":"PMC_25742746","title":"All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells.","date":"2015","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25742746","citation_count":62,"is_preprint":false},{"pmid":"35078784","id":"PMC_35078784","title":"Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.","date":"2022","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35078784","citation_count":59,"is_preprint":false},{"pmid":"30965686","id":"PMC_30965686","title":"A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30965686","citation_count":59,"is_preprint":false},{"pmid":"31534014","id":"PMC_31534014","title":"ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells.","date":"2019","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31534014","citation_count":55,"is_preprint":false},{"pmid":"30013043","id":"PMC_30013043","title":"Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30013043","citation_count":52,"is_preprint":false},{"pmid":"18178530","id":"PMC_18178530","title":"Expression of zebrafish aldh1a3 (raldh3) and absence of aldh1a1 in teleosts.","date":"2007","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/18178530","citation_count":52,"is_preprint":false},{"pmid":"25643237","id":"PMC_25643237","title":"Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.","date":"2015","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/25643237","citation_count":51,"is_preprint":false},{"pmid":"28792511","id":"PMC_28792511","title":"Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28792511","citation_count":50,"is_preprint":false},{"pmid":"21176222","id":"PMC_21176222","title":"Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.","date":"2010","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/21176222","citation_count":48,"is_preprint":false},{"pmid":"26770215","id":"PMC_26770215","title":"BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma.","date":"2015","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/26770215","citation_count":48,"is_preprint":false},{"pmid":"30293938","id":"PMC_30293938","title":"ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.","date":"2018","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30293938","citation_count":47,"is_preprint":false},{"pmid":"26517640","id":"PMC_26517640","title":"Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2.","date":"2015","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26517640","citation_count":46,"is_preprint":false},{"pmid":"22799327","id":"PMC_22799327","title":"Expression and functional role of ALDH1 in cervical carcinoma cells.","date":"2012","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/22799327","citation_count":44,"is_preprint":false},{"pmid":"12941160","id":"PMC_12941160","title":"Molecular cloning and baculovirus expression of the rabbit corneal aldehyde dehydrogenase (ALDH1A1) cDNA.","date":"2003","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12941160","citation_count":41,"is_preprint":false},{"pmid":"22144423","id":"PMC_22144423","title":"ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.","date":"2011","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/22144423","citation_count":40,"is_preprint":false},{"pmid":"17180597","id":"PMC_17180597","title":"Expression of retinaldehyde dehydrogenase (RALDH)2 and RALDH3 but not RALDH1 in the developing anterior pituitary glands of rats.","date":"2006","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/17180597","citation_count":36,"is_preprint":false},{"pmid":"28415606","id":"PMC_28415606","title":"TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28415606","citation_count":35,"is_preprint":false},{"pmid":"34079441","id":"PMC_34079441","title":"Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease.","date":"2021","source":"Frontiers in neural circuits","url":"https://pubmed.ncbi.nlm.nih.gov/34079441","citation_count":34,"is_preprint":false},{"pmid":"31665232","id":"PMC_31665232","title":"Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31665232","citation_count":34,"is_preprint":false},{"pmid":"33400378","id":"PMC_33400378","title":"Activation of ALDH1A1 by omeprazole reduces cell oxidative stress damage.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/33400378","citation_count":33,"is_preprint":false},{"pmid":"21804471","id":"PMC_21804471","title":"The expression of ALDH1 in cervical carcinoma.","date":"2011","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/21804471","citation_count":32,"is_preprint":false},{"pmid":"38169509","id":"PMC_38169509","title":"ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38169509","citation_count":31,"is_preprint":false},{"pmid":"26148881","id":"PMC_26148881","title":"The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26148881","citation_count":30,"is_preprint":false},{"pmid":"35582039","id":"PMC_35582039","title":"How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance.","date":"2020","source":"Cancer drug resistance (Alhambra, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35582039","citation_count":30,"is_preprint":false},{"pmid":"26113217","id":"PMC_26113217","title":"A Novel Approach for Overcoming Drug Resistance in Breast Cancer Chemotherapy by Targeting new Synthetic Curcumin Analogues Against Aldehyde Dehydrogenase 1 (ALDH1A1) and Glycogen Synthase Kinase-3 β (GSK-3β).","date":"2015","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/26113217","citation_count":29,"is_preprint":false},{"pmid":"29752431","id":"PMC_29752431","title":"DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29752431","citation_count":29,"is_preprint":false},{"pmid":"30344706","id":"PMC_30344706","title":"Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30344706","citation_count":28,"is_preprint":false},{"pmid":"35884498","id":"PMC_35884498","title":"A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35884498","citation_count":27,"is_preprint":false},{"pmid":"27068523","id":"PMC_27068523","title":"The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms.","date":"2016","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27068523","citation_count":27,"is_preprint":false},{"pmid":"29158806","id":"PMC_29158806","title":"Correlation of ALDH1 and Notch3 Expression: Clinical implication in Ovarian Carcinomas.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29158806","citation_count":26,"is_preprint":false},{"pmid":"32984354","id":"PMC_32984354","title":"Silybin Prevents Prostate Cancer by Inhibited the ALDH1A1 Expression in the Retinol Metabolism Pathway.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32984354","citation_count":26,"is_preprint":false},{"pmid":"22938492","id":"PMC_22938492","title":"High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas.","date":"2012","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/22938492","citation_count":26,"is_preprint":false},{"pmid":"27152521","id":"PMC_27152521","title":"Complex Behavior of ALDH1A1 and IGFBP1 in Liver Metastasis from a Colorectal Cancer.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27152521","citation_count":26,"is_preprint":false},{"pmid":"28123562","id":"PMC_28123562","title":"ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28123562","citation_count":25,"is_preprint":false},{"pmid":"30250298","id":"PMC_30250298","title":"Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30250298","citation_count":25,"is_preprint":false},{"pmid":"21336637","id":"PMC_21336637","title":"Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.","date":"2011","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/21336637","citation_count":24,"is_preprint":false},{"pmid":"35218575","id":"PMC_35218575","title":"Liver regeneration and ethanol detoxification: A new link in YAP regulation of ALDH1A1 during alcohol-related hepatocyte damage.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35218575","citation_count":24,"is_preprint":false},{"pmid":"27015121","id":"PMC_27015121","title":"Mining distinct aldehyde dehydrogenase 1 (ALDH1) isoenzymes in gastric cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27015121","citation_count":23,"is_preprint":false},{"pmid":"30430416","id":"PMC_30430416","title":"Immunolocalization of Cancer Stem Cells Marker ALDH1 and its Association with Tumor Budding in Oral Squamous Cell Carcinoma.","date":"2018","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30430416","citation_count":23,"is_preprint":false},{"pmid":"33241139","id":"PMC_33241139","title":"Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells.","date":"2020","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/33241139","citation_count":22,"is_preprint":false},{"pmid":"23332924","id":"PMC_23332924","title":"ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23332924","citation_count":22,"is_preprint":false},{"pmid":"29948941","id":"PMC_29948941","title":"Multifaceted Regulation of ALDH1A1 by Cdk5 in Alzheimer's Disease Pathogenesis.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29948941","citation_count":22,"is_preprint":false},{"pmid":"28476825","id":"PMC_28476825","title":"The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28476825","citation_count":22,"is_preprint":false},{"pmid":"33934107","id":"PMC_33934107","title":"Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet-induced mouse model of obesity.","date":"2021","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/33934107","citation_count":22,"is_preprint":false},{"pmid":"31580832","id":"PMC_31580832","title":"Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes.","date":"2019","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/31580832","citation_count":21,"is_preprint":false},{"pmid":"25031716","id":"PMC_25031716","title":"Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031716","citation_count":21,"is_preprint":false},{"pmid":"12234608","id":"PMC_12234608","title":"Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2).","date":"2002","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12234608","citation_count":21,"is_preprint":false},{"pmid":"27621650","id":"PMC_27621650","title":"ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27621650","citation_count":21,"is_preprint":false},{"pmid":"24248285","id":"PMC_24248285","title":"Cancer stem cell characteristics, ALDH1 expression in the invasive front of nasopharyngeal carcinoma.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24248285","citation_count":20,"is_preprint":false},{"pmid":"39317105","id":"PMC_39317105","title":"Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39317105","citation_count":19,"is_preprint":false},{"pmid":"28783931","id":"PMC_28783931","title":"Low Retinal Dehydrogenase 1 (RALDH1) Level in Prepubertal Boys with Autism Spectrum Disorder: A Possible Link to Dopamine Dysfunction?","date":"2017","source":"Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28783931","citation_count":19,"is_preprint":false},{"pmid":"22100631","id":"PMC_22100631","title":"Alcohol intake and folate antagonism via CYP2E1 and ALDH1: effects on oral carcinogenesis.","date":"2011","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/22100631","citation_count":19,"is_preprint":false},{"pmid":"26305673","id":"PMC_26305673","title":"Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26305673","citation_count":18,"is_preprint":false},{"pmid":"39223183","id":"PMC_39223183","title":"Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson's disease model.","date":"2024","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/39223183","citation_count":18,"is_preprint":false},{"pmid":"34417872","id":"PMC_34417872","title":"ASL expression in ALDH1A1+ neurons in the substantia nigra metabolically contributes to neurodegenerative phenotype.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34417872","citation_count":17,"is_preprint":false},{"pmid":"22581680","id":"PMC_22581680","title":"ALDH1 immunohistochemical expression and its significance in salivary adenoid cystic carcinoma.","date":"2012","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/22581680","citation_count":17,"is_preprint":false},{"pmid":"27569851","id":"PMC_27569851","title":"Expression of retinoic acid-metabolizing enzymes, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1 and CYP26C1 in canine testis during post-natal development.","date":"2016","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/27569851","citation_count":17,"is_preprint":false},{"pmid":"35574006","id":"PMC_35574006","title":"Global Deletion of ALDH1A1 and ALDH1A2 Genes Does Not Affect Viability but Blocks Spermatogenesis.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35574006","citation_count":16,"is_preprint":false},{"pmid":"35173149","id":"PMC_35173149","title":"Long non-coding ROR promotes the progression of papillary thyroid carcinoma through regulation of the TESC/ALDH1A1/TUBB3/PTEN axis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35173149","citation_count":16,"is_preprint":false},{"pmid":"35028852","id":"PMC_35028852","title":"Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35028852","citation_count":15,"is_preprint":false},{"pmid":"34702328","id":"PMC_34702328","title":"Synaptic dysfunction of Aldh1a1 neurons in the ventral tegmental area causes impulsive behaviors.","date":"2021","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/34702328","citation_count":15,"is_preprint":false},{"pmid":"39107297","id":"PMC_39107297","title":"ALDH1A1 promotes immune escape of tumor cells through ZBTB7B-glycolysis pathway.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39107297","citation_count":14,"is_preprint":false},{"pmid":"37639589","id":"PMC_37639589","title":"Leveraging intracellular ALDH1A1 activity for selective cancer stem-like cell labeling and targeted treatment via in vivo click reaction.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37639589","citation_count":14,"is_preprint":false},{"pmid":"26230297","id":"PMC_26230297","title":"Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis.","date":"2015","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26230297","citation_count":14,"is_preprint":false},{"pmid":"34758328","id":"PMC_34758328","title":"Genomic expansion of Aldh1a1 protects beavers against high metabolic aldehydes from lipid oxidation.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34758328","citation_count":14,"is_preprint":false},{"pmid":"30911937","id":"PMC_30911937","title":"UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells.","date":"2019","source":"Metabolomics : Official journal of the Metabolomic Society","url":"https://pubmed.ncbi.nlm.nih.gov/30911937","citation_count":14,"is_preprint":false},{"pmid":"32630086","id":"PMC_32630086","title":"L1CAM, CA9, KLK6, HPN, and ALDH1A1 as Potential Serum Markers in Primary and Metastatic Colorectal Cancer Screening.","date":"2020","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32630086","citation_count":14,"is_preprint":false},{"pmid":"35056791","id":"PMC_35056791","title":"Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35056791","citation_count":13,"is_preprint":false},{"pmid":"39979263","id":"PMC_39979263","title":"Activity-based sensing reveals elevated labile copper promotes liver aging via hepatic ALDH1A1 depletion.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39979263","citation_count":13,"is_preprint":false},{"pmid":"33391379","id":"PMC_33391379","title":"Clinicopathological Significance of Tumor Stem Cell Markers ALDH1 and CD133 in Colorectal Carcinoma.","date":"2020","source":"Iranian journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33391379","citation_count":13,"is_preprint":false},{"pmid":"37298333","id":"PMC_37298333","title":"The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37298333","citation_count":13,"is_preprint":false},{"pmid":"23046827","id":"PMC_23046827","title":"Psychotropics regulate Skp1a, Aldh1a1, and Hspa8 transcription--potential to delay Parkinson's disease.","date":"2012","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23046827","citation_count":13,"is_preprint":false},{"pmid":"32305326","id":"PMC_32305326","title":"ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32305326","citation_count":13,"is_preprint":false},{"pmid":"38701866","id":"PMC_38701866","title":"ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38701866","citation_count":13,"is_preprint":false},{"pmid":"35858554","id":"PMC_35858554","title":"KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35858554","citation_count":12,"is_preprint":false},{"pmid":"35412614","id":"PMC_35412614","title":"Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/35412614","citation_count":12,"is_preprint":false},{"pmid":"30265376","id":"PMC_30265376","title":"Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30265376","citation_count":12,"is_preprint":false},{"pmid":"34897678","id":"PMC_34897678","title":"EHMT1 promotes tumor progression and maintains stemness by regulating ALDH1A1 expression in alveolar rhabdomyosarcoma.","date":"2022","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34897678","citation_count":11,"is_preprint":false},{"pmid":"37867947","id":"PMC_37867947","title":"Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37867947","citation_count":11,"is_preprint":false},{"pmid":"34287293","id":"PMC_34287293","title":"Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients.","date":"2021","source":"Current oncology (Toronto, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/34287293","citation_count":11,"is_preprint":false},{"pmid":"33744437","id":"PMC_33744437","title":"Development of new disulfiram analogues as ALDH1a1-selective inhibitors.","date":"2021","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/33744437","citation_count":11,"is_preprint":false},{"pmid":"23084350","id":"PMC_23084350","title":"ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma.","date":"2012","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/23084350","citation_count":11,"is_preprint":false},{"pmid":"27630305","id":"PMC_27630305","title":"Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.","date":"2016","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27630305","citation_count":11,"is_preprint":false},{"pmid":"40055736","id":"PMC_40055736","title":"Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer.","date":"2025","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40055736","citation_count":10,"is_preprint":false},{"pmid":"32701933","id":"PMC_32701933","title":"Overexpression of ALDH1 and EMT marker profile are linked with unfavorable outcome in head and neck cancer.","date":"2020","source":"Medicina oral, patologia oral y cirugia bucal","url":"https://pubmed.ncbi.nlm.nih.gov/32701933","citation_count":10,"is_preprint":false},{"pmid":"36590957","id":"PMC_36590957","title":"Reliability of CD44, CD24, and ALDH1A1 immunohistochemical staining: Pathologist assessment compared to quantitative image analysis.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36590957","citation_count":10,"is_preprint":false},{"pmid":"25344211","id":"PMC_25344211","title":"ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25344211","citation_count":10,"is_preprint":false},{"pmid":"33460998","id":"PMC_33460998","title":"The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.","date":"2021","source":"Annals of diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33460998","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54602,"output_tokens":8300,"usd":0.144153},"stage2":{"model":"claude-opus-4-6","input_tokens":12095,"output_tokens":4722,"usd":0.267788},"total_usd":0.411941,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"ALDH1A1 (Raldh1) functions as a retinaldehyde dehydrogenase in the second step of retinoic acid synthesis, acting downstream of alcohol dehydrogenase ADH1 to oxidize retinaldehyde to retinoic acid in adult mice. Raldh1-/- mice showed 72% reduction in serum RA levels and 2.5-fold accumulation of retinaldehyde after retinol dosing, establishing the enzymatic pathway position.\",\n      \"method\": \"Genetic knockout mouse model (Raldh1-/-), serum RA/retinaldehyde measurement, epistasis with Adh1-/- mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic epistasis with quantitative metabolite measurement, replicated across two knockout lines\",\n      \"pmids\": [\"12851412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ALDH1A1 (Raldh1) is expressed in the dorsal neural retina and provides retinoic acid signaling required for dorsal retina development; Raldh1-/- mice lose RARE-lacZ RA reporter activity in dorsal retina at E16.5, demonstrating its non-redundant role in late dorsal RA synthesis when Raldh3 is absent from dorsal retina.\",\n      \"method\": \"Targeted gene disruption, RARE-lacZ transgenic reporter, retrograde ganglion cell labeling, electroretinography\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean knockout with multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"12808103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rabbit and human recombinant ALDH1A1 proteins efficiently oxidize lipid peroxidation aldehydes including hexanal (Km = 3.5 µM), 4-hydroxynonenal (Km = 2.1 µM), and malondialdehyde (Km = 14.0 µM), indicating a corneal cytoprotective function against UV-induced oxidative damage.\",\n      \"method\": \"Baculovirus expression and affinity purification of recombinant protein, in vitro enzymatic kinetic assay\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted recombinant enzyme with kinetic constants for multiple substrates\",\n      \"pmids\": [\"12941160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ALDH1A1 possesses both dehydrogenase and esterase activities; the competitive irreversible inhibitor DIMATE acts via ALDH1A1 esterase activity to release methanethiol, which lowers mitochondrial glutathione and induces apoptosis in cells overexpressing BCL2. This identifies a mechanism by which ALDH1 enzymatic inhibition can overcome drug resistance.\",\n      \"method\": \"In vitro enzyme inhibition assay, ALDH1-transfected L1210 cells, DNA fragmentation apoptosis assay, intramitochondrial glutathione measurement\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay plus cell-based mechanistic follow-up, single study\",\n      \"pmids\": [\"12234608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ALDH1A1 is a direct transcriptional target of EZH2 in epithelial ovarian cancer; EZH2 and H3K27Me3 bind the ALDH1A1 genomic locus, and EZH2 knockdown de-represses ALDH1A1 expression in a H3K27Me3-dependent manner, as validated by ChIP-seq and gene expression profiling.\",\n      \"method\": \"ChIP-seq for EZH2/H3K27Me3, EZH2 knockdown with gene expression microarray, ChIP validation\",\n      \"journal\": \"Cancer prevention research (Philadelphia, Pa.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP-seq plus functional validation by knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"22144423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ALDH1A1 in multiple myeloma generates the RXRα ligand 9-cis retinoic acid (not the RARα ligand ATRA), which activates RXRα to upregulate NEK2 kinase expression, which in turn increases drug-efflux pump activity (ABCB1) and promotes drug resistance. shRNA knockdown of NEK2 decreased drug efflux and resistance.\",\n      \"method\": \"Enforced ALDH1A1 expression in myeloma cells, shRNA knockdown of NEK2, mRNA/protein quantification, drug efflux assay, in vivo tumor formation\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (overexpression, knockdown, metabolite identification, drug efflux assay, in vivo) in single study\",\n      \"pmids\": [\"25230277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"β-Catenin directly regulates ALDH1A1 transcription in ovarian cancer spheroids; β-catenin co-immunoprecipitates with the ALDH1A1 promoter, and β-catenin knockdown decreases ALDH1A1 expression and disrupts spheroid formation.\",\n      \"method\": \"Co-immunoprecipitation with ALDH1A1 promoter, siRNA knockdown, spheroid formation assay, small-molecule ALDH1A1 inhibitor (A37)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP/co-IP of promoter, siRNA knockdown, pharmacological inhibition with concordant phenotypes\",\n      \"pmids\": [\"24954508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DDB2 (DNA damage-binding protein 2) represses ALDH1A1 transcription by binding to the ALDH1A1 promoter, promoting H3K27me3 enrichment, and competing with the transcription factor C/EBPβ for promoter occupancy, thereby suppressing ovarian cancer cell dedifferentiation.\",\n      \"method\": \"ChIP assay, promoter binding competition assay, DDB2 knockdown/overexpression, H3K27me3 enrichment at ALDH1A1 promoter\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with multiple orthogonal functional readouts, mechanistic promoter competition established\",\n      \"pmids\": [\"29752431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cdk5 phosphorylates ALDH1A1, which prevents its ubiquitylation and increases protein stability; Cdk5-mediated phosphorylation also alters ALDH1A1 from a tetrameric to a highly active monomeric state, increasing dehydrogenase activity. Under sustained oxidative stress, Cdk5 ultimately inactivates ALDH1A1.\",\n      \"method\": \"In vitro kinase assay, phosphorylation-site mutagenesis, ubiquitylation assay, native gel analysis of oligomeric state, dehydrogenase activity assay\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mutagenesis, oligomeric state analysis, and activity measurement\",\n      \"pmids\": [\"29948941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID1A recruits HDAC1 to the ALDH1A1 promoter, decreasing histone H3K27 acetylation and suppressing ALDH1A1 transcription. ARID1A knockout via CRISPR/Cas9 increases H3K27 acetylation at the ALDH1A1 promoter and markedly upregulates ALDH1A1 expression and ALDH enzyme activity.\",\n      \"method\": \"CRISPR/Cas9 knockout, ChIP assay for ARID1A and HDAC1 at ALDH1A1 promoter, H3K27 acetylation ChIP, microarray gene expression\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with ChIP-based mechanistic validation of promoter regulation\",\n      \"pmids\": [\"31665232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALDH1A1 contributes to PARP inhibitor resistance in BRCA2-deficient ovarian cancer cells by enhancing microhomology-mediated end joining (MMEJ) DNA repair. ALDH1A1 knockdown reduced MMEJ activity as measured by an intrachromosomal MMEJ reporter, and selective ALDH1A1 inhibitor NCT-501 synergized with olaparib in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, intrachromosomal MMEJ reporter assay, selective ALDH1A1 inhibitor (NCT-501), xenograft model\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional MMEJ reporter plus pharmacological and genetic inhibition with in vivo validation\",\n      \"pmids\": [\"31534014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALDH1A1 inhibition with CM37 increases intracellular ROS accumulation, which leads to DNA damage (γH2AX induction) and upregulation of DNA damage response genes (NEIL3), reducing ovarian cancer cell viability in ALDH+ cancer stem cell populations.\",\n      \"method\": \"ALDH1A1 small-molecule inhibitor CM37, siRNA knockdown, γH2AX immunofluorescence, ROS measurement, in vivo limiting dilution assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic inhibition with mechanistic ROS/DNA damage readout, single study\",\n      \"pmids\": [\"30965686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALDH1A1 enzymatic activity decreases intracellular pH in breast cancer tumor-initiating cells, promoting phosphorylation of TAK1, activating NF-κB signaling, and increasing GM-CSF secretion, which drives expansion of myeloid-derived suppressor cells and creates an immunosuppressive tumor microenvironment.\",\n      \"method\": \"ALDH1A1 enzymatic inhibitor (disulfiram), siRNA/shRNA knockdown, intracellular pH measurement, TAK1 phosphorylation assay, GM-CSF ELISA, MDSC flow cytometry, syngeneic tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking enzymatic activity to intracellular pH, TAK1/NFκB signaling, and immune phenotype in vitro and in vivo\",\n      \"pmids\": [\"34580061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A9 upregulates ALDH1A1 expression and activates the downstream retinoic acid (RA) signaling pathway in osimertinib-refractory EGFR-mutant lung cancer cells; genetic repression of S100A9, ALDH1A1, or RA receptors (RAR) dramatically reduces brain metastasis.\",\n      \"method\": \"Genetic knockdown of S100A9/ALDH1A1/RARs, pan-RAR antagonist treatment, brain metastasis mouse models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic perturbations with consistent in vivo phenotypes establishing pathway order\",\n      \"pmids\": [\"35078784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TAZ transcriptional co-activator induces ALDH1A1 transcription by activating the ALDH1A1 promoter through interaction with the TEAD transcription factor. CRISPR knockout or pharmacological inhibition of ALDH1A1 suppresses TAZ-induced lung cancer stem cell and tumorigenic phenotypes.\",\n      \"method\": \"RNA-seq, ALDH1A1 promoter-luciferase reporter assay, TAZ-TEAD interaction assay, CRISPR knockout, ALDH1A1 inhibitor (A37), in vivo tumor formation\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter assay, CRISPR KO and pharmacological inhibition with in vivo tumor readout\",\n      \"pmids\": [\"28415606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"STAT3 is a transcriptional activator of ALDH1 isozymes; TESC activates IGF1Rβ by direct recruitment of c-Src to the IGF1Rβ complex, leading to STAT3 activation that upregulates ALDH1 expression to maintain cancer stem cell properties and radioresistance.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, co-immunoprecipitation of c-Src/IGF1Rβ, TESC knockdown, IGF1R inhibitor (AG1024)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase assay plus co-IP and pharmacological inhibition, single study\",\n      \"pmids\": [\"30013043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"YAP (Yes-associated protein) transcriptionally activates ALDH1A1; ectopic expression of human ALDH1A1 in Yap1 hepatocyte-specific knockout mice reduces hepatic necrosis, oxidative stress, ECM remodeling, and inflammation during alcohol/CCl4-induced liver damage, demonstrating a protective detoxification role downstream of YAP.\",\n      \"method\": \"AAV8-Cre-mediated hepatocyte-specific Yap1 knockout, whole-genome transcriptomics, ectopic ALDH1A1 expression rescue experiment, hyperactive YAP mutant transactivation assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with rescue by ectopic ALDH1A1, transcriptomic confirmation, single study\",\n      \"pmids\": [\"35218575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALDH1A1 and ALDH1A2 together are required for RA synthesis in Sertoli cells to initiate spermatogonial differentiation; global double knockout of Aldh1a1 and Aldh1a2 blocks spermatogenesis completely, and remaining Aldh1a3 activity cannot compensate. Cell-specific deletion showed that Sertoli cell RA synthesis is required but germ cell RA synthesis is not.\",\n      \"method\": \"Global gene deletion (Aldh1a1 KO mouse), Cre-loxP conditional Aldh1a2 deletion in Sertoli cells and germ cells, histological analysis of spermatogenesis\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockouts with cell-type-specific dissection of function, multiple combinations tested\",\n      \"pmids\": [\"35574006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"5-Nitrofuran nifuroxazide is selectively bio-activated by ALDH1A1/1A3 enzymes; it both oxidizes ALDH1 and is converted to cytotoxic metabolites in a two-hit pro-drug mechanism. ALDH1A3 loss-of-function mutations confer resistance to nifuroxazide, confirming that ALDH1 enzymatic activity is required for drug activation.\",\n      \"method\": \"In vitro ALDH1A1 oxidation assay, ALDH1A3 loss-of-function mutagenesis, cytotoxicity assays, in vivo tumor xenograft\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay plus mutagenesis confirming enzyme-dependent drug activation\",\n      \"pmids\": [\"30293938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Omeprazole, after photoactivation, binds in the active site of ALDH1A1 and activates it, protecting eukaryotic cells from oxidative stress-induced lipid aldehyde accumulation. Disulfiram (ALDH inhibitor) blocks this protection, confirming ALDH1A1-mediated cell defense.\",\n      \"method\": \"ALDH total activity assay in cell suspensions, lipid aldehyde quantification, cell viability assay, disulfiram inhibition control, mitochondrial function assessment\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological activation and inhibition with multiple functional readouts, single study\",\n      \"pmids\": [\"33400378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALDH1A1 induces resistance to CHOP chemotherapy in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway; ALDH1A1 overexpression upregulates p-STAT3, and JAK2/STAT3 pathway inhibitor WP1066 negates the resistance conferred by ALDH1A1 overexpression.\",\n      \"method\": \"ALDH1A1 overexpression, shRNA knockdown, JAK2/STAT3 inhibitor (WP1066), caspase activity assay, western blot for p-STAT3\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression, knockdown, and pharmacological rescue identifying JAK2/STAT3 as mediator, single study\",\n      \"pmids\": [\"27621650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EHMT1 methyltransferase does not directly bind the ALDH1A1 promoter but activates it by stabilizing C/EBPβ, a known transcriptional regulator of ALDH1A1 expression. EHMT1 depletion reduces ALDH1A1 expression, decreasing tumorsphere formation and tumor progression in rhabdomyosarcoma.\",\n      \"method\": \"RNA sequencing, EHMT1 knockdown, ChIP assay, C/EBPβ stabilization assay, ALDH1A1 inhibitor, tumorsphere assay, mouse xenograft\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based mechanism with functional rescue, single study\",\n      \"pmids\": [\"34897678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of PBRM1 (PBAF SWI/SNF subunit) results in de novo H3K4me3 gains at the ALDH1A1 promoter, activating ALDH1A1 transcription. ARID2 (another PBAF subunit) remains bound after PBRM1 loss and is essential for ALDH1A1 upregulation, while BRG1 is dispensable. Increased ALDH1A1 enhances tumorigenic potential of ccRCC cells.\",\n      \"method\": \"RNA-seq, H3K4me3 ChIP-seq, ATAC-seq, PBRM1/ARID2 knockdown, BRG1 knockdown, ccRCC cell tumorigenicity assay\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — integrated multi-omic epigenomic approach with multiple genetic perturbations identifying specific chromatin mechanism\",\n      \"pmids\": [\"35412614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALDH1A1 is modified by 2-hydroxyisobutyrylation at lysine-260 (K260hib); higher K260hib modification promotes ALDH1A1 protein degradation through chaperone-mediated autophagy (CMA) and is regulated by HDAC2/3. Lower K260hib (as seen in bladder cancer) stabilizes ALDH1A1 protein and enhances its activity.\",\n      \"method\": \"Protein modification omics, K260hib-specific mutagenesis, HDAC2/3 inhibition assays, CMA pathway analysis, bladder cancer cell functional assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel PTM identified by omics with mutagenesis and degradation pathway confirmation, single study\",\n      \"pmids\": [\"37867947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KRAS inhibitors dephosphorylate GTF2I at S784 via ERK, blocking its nuclear translocation and upregulating ALDH1A1 expression. Elevated ALDH1A1 suppresses KRAS inhibitor efficacy by detoxifying lipid aldehydes, boosting NADH and RA synthesis, activating RARA function and the CREB1/GPX4 pathway, stimulating lipid droplet production in a pH-dependent manner, and thereby counteracting ferroptosis.\",\n      \"method\": \"ALDH1A1 knockout/inhibitor, GTF2I phosphorylation analysis, CREB1/GPX4 pathway analysis, lipid droplet quantification, patient-derived organoids, xenograft models\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanisms tested with genetic KO and PDO models, single study\",\n      \"pmids\": [\"39317105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In the ventral tegmental area, Aldh1a1 neurons are a subtype of GABAergic inhibitory interneurons that synthesize GABA using ALDH1A1 rather than GAD, project inhibitory synapses onto excitatory glutamate neurons in the intermediate lateral septum (EGNIS), and receive inputs from layer 5b medial prefrontal cortex pyramidal neurons. L5PN→Aldh1a1 synaptic transmission undergoes LTP, and dysfunction of this circuit produces impulsive behaviors.\",\n      \"method\": \"Aldh1a1-CRE knock-in mice, anterograde/retrograde synaptic tracing, optogenetic circuit manipulation, LTP electrophysiology, genetic silencing, exogenous Aldh1a1 rescue in AD mice\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — circuit mapping with multiple genetic and electrophysiological methods plus rescue experiment\",\n      \"pmids\": [\"34702328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A1 interacts with the transcription factor ZBTB7B; ALDH1A1 promotes ZBTB7B SUMOylation to stabilize its activity, and ZBTB7B binds the LDHA promoter to regulate glycolysis. ALDH1A1 deficiency reduces ZBTB7B-dependent LDHA expression, decreasing tumor glycolysis and reducing immune evasion.\",\n      \"method\": \"RNA-seq, luciferase reporter assay, ChIP-qPCR for ZBTB7B at LDHA promoter, Co-IP, SUMOylation assay, xenograft in immune-normal mice, flow cytometry\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, co-IP, and luciferase assay establishing pathway, single study\",\n      \"pmids\": [\"39107297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Labile hepatic copper (Cu) activity increases with age in mice and inversely correlates with ALDH1A1 activity. Treatment with copper chelator ATN-224 restores Cu homeostasis and preserves ALDH1A1 protective activity, establishing a direct mechanistic link between Cu dysregulation and ALDH1A1 functional decline in liver aging.\",\n      \"method\": \"Activity-based Cu(I) imaging probes, photoacoustic glutathione imaging, longitudinal aging mouse study, Cu chelator (ATN-224) treatment, ALDH1A1 activity assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel activity-based probes with functional rescue by chelation, single study\",\n      \"pmids\": [\"39979263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ubiquitin ligase FBXL12 ubiquitinates ALDH1A1, targeting it for degradation. Sorcin normally sequesters PAX5 in the cytoplasm; disruption of the sorcin-PAX5 interaction (e.g., by celastrol binding Cys194 of sorcin) allows PAX5 nuclear translocation, which induces FBXL12 expression, increases ALDH1A1 ubiquitylation, depletes ALDH1A1 protein, and promotes ferroptosis in pancreatic cancer cells.\",\n      \"method\": \"Co-IP, ChIP assay, luciferase reporter, proteomics, FBXL12 overexpression/knockdown, ubiquitylation assay, celastrol docking and functional studies\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods identifying ubiquitin writer FBXL12 and upstream PAX5 regulation, single study\",\n      \"pmids\": [\"40055736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A1 drives prostate cancer metastasis and radioresistance through interplay with androgen receptor (AR) and retinoid receptor (RAR) transcriptional programs; RNAseq and ChIP analyses identify PLK3 as a transcriptional target oppositely regulated by ALDH1A1 (activating) and ALDH1A3 (repressing) in RAR/AR-dependent manner, contributing to proliferation, migration, DNA repair, and radioresistance.\",\n      \"method\": \"ALDH1A1/ALDH1A3 genetic silencing, RNAseq, ChIP, zebrafish and murine xenograft models, comparative IHC of clinical specimens\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and RNAseq with in vivo validation, single study identifying transcriptional mechanism\",\n      \"pmids\": [\"38169509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Melanoma cells overexpressing ALDH1A1 resist BRAF/MEK inhibitors (vemurafenib/trametinib) through activation of PI3K/AKT signaling rather than the MAPK axis; pharmacological inhibition of ALDH1A1 activity downregulates AKT phosphorylation and partially restores drug sensitivity, while PI3K/AKT inhibition also rescues sensitivity.\",\n      \"method\": \"ALDH1A1 overexpression, ALDH1A1 pharmacological inhibitor, PI3K/AKT inhibitor, western blot for p-AKT, drug sensitivity assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor combined with pathway inhibitor rescue establishing PI3K/AKT as mediator, single study\",\n      \"pmids\": [\"38701866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ALDH1A1 inhibition with compound 974 suppresses platinum-induced cellular senescence and the senescence-associated secretory phenotype (SASP) in ovarian cancer stem cells, as demonstrated by transcriptomic sequencing and functional senescence assays, linking ALDH1A1 to regulation of chemotherapy-induced senescence.\",\n      \"method\": \"ALDH1A1 inhibitor (compound 974), transcriptomic RNA sequencing, functional senescence assays, in vivo limiting dilution assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with transcriptomic and functional confirmation, single study\",\n      \"pmids\": [\"35884498\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALDH1A1 is a cytoplasmic NAD+-dependent aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid (acting downstream of ADH1 in retinol metabolism) and detoxifies lipid peroxidation aldehydes; its transcription is regulated by multiple epigenetic mechanisms (EZH2/H3K27me3, ARID1A/HDAC1, PBRM1/ARID2, DDB2/C/EBPβ, and activators including β-catenin, TAZ-TEAD, STAT3, and YAP), its protein stability is controlled by Cdk5 phosphorylation at a site that blocks ubiquitylation and by K260 2-hydroxyisobutyrylation-triggered CMA degradation via FBXL12, and its enzymatic activity drives diverse downstream pathways including 9-cis-RA/RXRα/NEK2-mediated drug efflux, intracellular pH reduction/TAK1/NFκB/GM-CSF-mediated immunosuppression, MMEJ-dependent DNA repair resistance, PI3K/AKT activation, ZBTB7B/LDHA glycolysis regulation, and ferroptosis suppression via CREB1/GPX4, while in GABAergic neurons of the VTA it functions as a GABA-synthetic enzyme whose activity is required for circuit-level control of impulse behavior.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ALDH1A1 is a cytoplasmic NAD⁺-dependent aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid and detoxifies lipid peroxidation-derived aldehydes, thereby serving as a central node linking retinoid signaling, redox homeostasis, and cellular differentiation. As the principal retinaldehyde dehydrogenase acting downstream of ADH1, ALDH1A1 generates retinoic acid species including 9-cis-RA that activate RAR/RXRα transcriptional programs, driving processes as diverse as dorsal retinal patterning, spermatogonial differentiation, drug-efflux pump upregulation via RXRα/NEK2, and ferroptosis resistance through CREB1/GPX4 [PMID:12851412, PMID:12808103, PMID:25230277, PMID:35574006, PMID:39317105]. Its transcription is regulated by multiple chromatin remodeling and signaling axes—repressed by EZH2/H3K27me3, ARID1A/HDAC1, DDB2/C/EBPβ competition, and PBRM1-containing PBAF, and activated by β-catenin, TAZ-TEAD, STAT3, and YAP—while protein stability is controlled by Cdk5 phosphorylation that blocks ubiquitylation and by FBXL12-mediated ubiquitin-dependent degradation and K260 2-hydroxyisobutyrylation-triggered chaperone-mediated autophagy [PMID:22144423, PMID:31665232, PMID:29752431, PMID:35412614, PMID:29948941, PMID:40055736, PMID:37867947]. Beyond canonical aldehyde metabolism, ALDH1A1 enzymatic activity lowers intracellular pH to activate TAK1/NF-κB/GM-CSF immunosuppressive signaling, promotes MMEJ-dependent DNA repair, interacts with ZBTB7B to regulate glycolysis via LDHA, and functions as a GABA-synthetic enzyme in VTA GABAergic neurons where it controls inhibitory circuit-level regulation of impulsive behavior [PMID:34580061, PMID:31534014, PMID:39107297, PMID:34702328].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"ALDH1A1's biochemical identity as a retinaldehyde dehydrogenase and lipid aldehyde detoxifier was established, defining its dual enzymatic substrate repertoire and placing it in the retinol→retinaldehyde→retinoic acid pathway downstream of ADH1.\",\n      \"evidence\": \"Raldh1⁻/⁻ knockout mice with serum RA/retinaldehyde quantification and epistasis with Adh1⁻/⁻; recombinant enzyme kinetics for hexanal, 4-HNE, and MDA; RARE-lacZ reporter in dorsal retina of Raldh1⁻/⁻ mice\",\n      \"pmids\": [\"12851412\", \"12941160\", \"12808103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure-based substrate selectivity determinants not resolved\", \"Relative contribution of ALDH1A1 vs ALDH1A2/1A3 to systemic RA not fully quantified\", \"Retinaldehyde vs lipid aldehyde preference in different tissues not systematically compared\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The first transcriptional repression mechanism was identified: EZH2 deposits H3K27me3 at the ALDH1A1 locus to silence it, revealing that ALDH1A1 expression is under Polycomb-mediated epigenetic control.\",\n      \"evidence\": \"ChIP-seq for EZH2 and H3K27me3 at ALDH1A1 locus, EZH2 knockdown de-repression in ovarian cancer cells\",\n      \"pmids\": [\"22144423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EZH2-mediated repression operates in non-cancer tissues unknown\", \"Specific PRC2 recruitment mechanism to ALDH1A1 locus not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The downstream signaling output of ALDH1A1's RA product was delineated: 9-cis-RA activates RXRα to upregulate NEK2, which increases ABCB1 drug-efflux activity, establishing the first complete enzymatic product→receptor→effector pathway for ALDH1A1-mediated drug resistance.\",\n      \"evidence\": \"Enforced ALDH1A1 expression in myeloma cells, NEK2 shRNA, drug efflux assay, in vivo tumor model\",\n      \"pmids\": [\"25230277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all-trans-RA contributes through RAR-dependent pathways in this context not excluded\", \"NEK2 regulation of ABCB1 mechanism not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"β-catenin was identified as a direct transcriptional activator at the ALDH1A1 promoter, linking Wnt signaling to ALDH1A1 expression and cancer stemness.\",\n      \"evidence\": \"ChIP/co-IP of β-catenin at ALDH1A1 promoter, siRNA knockdown, spheroid formation assay in ovarian cancer\",\n      \"pmids\": [\"24954508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TCF/LEF binding site identity at ALDH1A1 promoter not mapped\", \"Interplay between β-catenin activation and EZH2 repression at the same locus not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"TAZ-TEAD was established as another transcriptional activator of ALDH1A1, expanding the set of oncogenic inputs that converge on ALDH1A1 transcription to include Hippo pathway effectors.\",\n      \"evidence\": \"ALDH1A1 promoter-luciferase, TAZ-TEAD interaction assay, CRISPR KO of ALDH1A1, ALDH1A1 inhibitor A37, in vivo tumor formation\",\n      \"pmids\": [\"28415606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TEAD binding elements in ALDH1A1 promoter not mapped at base-pair resolution\", \"Relative contribution of TAZ vs YAP at this promoter unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Post-translational regulation of ALDH1A1 was resolved: Cdk5 phosphorylation prevents ubiquitylation and stabilizes ALDH1A1 protein while converting it from an inactive tetramer to a highly active monomer, establishing the first kinase-dependent control of ALDH1A1 enzymatic output.\",\n      \"evidence\": \"In vitro kinase assay, phosphosite mutagenesis, ubiquitylation assay, native gel oligomeric state analysis, dehydrogenase activity measurement\",\n      \"pmids\": [\"29948941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation site identity not fully mapped across all Cdk5 sites\", \"Identity of the E3 ubiquitin ligase counteracted by Cdk5 phosphorylation was unknown at that time\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Additional chromatin-level repression mechanisms were defined: DDB2 competes with C/EBPβ for ALDH1A1 promoter occupancy and promotes H3K27me3, while ARID1A recruits HDAC1 to reduce H3K27 acetylation, revealing that multiple SWI/SNF and DNA-damage factors independently silence ALDH1A1.\",\n      \"evidence\": \"ChIP for DDB2, C/EBPβ competition, H3K27me3 enrichment; CRISPR KO of ARID1A with HDAC1 ChIP at ALDH1A1 promoter\",\n      \"pmids\": [\"29752431\", \"31665232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchical relationship among EZH2, DDB2, and ARID1A repression at ALDH1A1 not dissected\", \"Whether these mechanisms operate simultaneously or context-specifically unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A non-canonical function was uncovered: ALDH1A1 enhances microhomology-mediated end joining (MMEJ) DNA repair, contributing to PARP inhibitor resistance in BRCA2-deficient cells—the first link between ALDH1A1 and a specific DNA repair pathway.\",\n      \"evidence\": \"siRNA knockdown, intrachromosomal MMEJ reporter assay, selective ALDH1A1 inhibitor NCT-501, xenograft model\",\n      \"pmids\": [\"31534014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism by which ALDH1A1 promotes MMEJ is unknown—whether via RA signaling or direct protein interaction unresolved\", \"Whether this extends to other alternative end-joining pathways not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ALDH1A1 enzymatic activity was shown to lower intracellular pH, triggering TAK1 phosphorylation, NF-κB activation, and GM-CSF secretion that expands myeloid-derived suppressor cells, establishing a metabolite-to-immune-evasion signaling axis.\",\n      \"evidence\": \"Disulfiram inhibition and siRNA/shRNA knockdown, intracellular pH measurement, TAK1 phosphorylation, GM-CSF ELISA, MDSC flow cytometry, syngeneic tumor models\",\n      \"pmids\": [\"34580061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which ALDH1A1-generated metabolite lowers pH not identified\", \"Whether this pH-dependent mechanism operates in non-breast-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"In the brain, ALDH1A1 was identified as a GABA-synthetic enzyme in VTA GABAergic interneurons; these Aldh1a1⁺ neurons project to the intermediate lateral septum and receive mPFC layer 5b input, forming a circuit whose dysfunction produces impulsive behavior.\",\n      \"evidence\": \"Aldh1a1-CRE knock-in mice, anterograde/retrograde tracing, optogenetic manipulation, LTP electrophysiology, genetic silencing and rescue in AD mice\",\n      \"pmids\": [\"34702328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ALDH1A1-derived GABA synthesis is quantitatively significant vs GAD-mediated synthesis not measured\", \"Mechanism of GABA synthesis by ALDH1A1 (substrate identity) not biochemically reconstituted\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cooperative RA synthesis by ALDH1A1 and ALDH1A2 in Sertoli cells was shown to be essential for spermatogonial differentiation; double knockout blocked spermatogenesis completely, establishing tissue-specific non-redundancy among ALDH1A isoforms.\",\n      \"evidence\": \"Aldh1a1 KO combined with Cre-loxP conditional Aldh1a2 deletion in Sertoli cells vs germ cells, histological analysis\",\n      \"pmids\": [\"35574006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative RA contribution of ALDH1A1 vs ALDH1A2 in Sertoli cells not quantified\", \"Downstream RA target genes in spermatogonial differentiation not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"PBAF SWI/SNF chromatin remodeling was linked to ALDH1A1: PBRM1 loss causes de novo H3K4me3 at the ALDH1A1 promoter, and residual ARID2 is required for this activation, distinguishing PBAF-dependent regulation from canonical BRG1-dependent remodeling.\",\n      \"evidence\": \"RNA-seq, H3K4me3 ChIP-seq, ATAC-seq, PBRM1/ARID2/BRG1 knockdown in ccRCC cells\",\n      \"pmids\": [\"35412614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARID2 activates ALDH1A1 in the absence of PBRM1 mechanistically unclear\", \"Whether this applies outside ccRCC not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A novel PTM-degradation axis was identified: K260 2-hydroxyisobutyrylation (regulated by HDAC2/3) triggers ALDH1A1 degradation via chaperone-mediated autophagy, providing a non-ubiquitin mechanism for ALDH1A1 protein turnover.\",\n      \"evidence\": \"K260hib-specific mutagenesis, HDAC2/3 inhibition, CMA pathway analysis in bladder cancer cells\",\n      \"pmids\": [\"37867947\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The CMA receptor (LAMP2A) interaction with K260hib-modified ALDH1A1 not directly demonstrated\", \"Writer enzyme for K260hib not identified\", \"Single study awaiting independent replication\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"ALDH1A1's role in ferroptosis resistance was mechanistically dissected: ALDH1A1 detoxifies lipid aldehydes, generates NADH and RA, activates RARA and the CREB1/GPX4 axis, and promotes lipid droplet formation, collectively counteracting ferroptosis induced by KRAS inhibitors.\",\n      \"evidence\": \"ALDH1A1 knockout/inhibitor, GTF2I phosphorylation analysis, CREB1/GPX4 pathway assays, lipid droplet quantification, PDOs and xenografts\",\n      \"pmids\": [\"39317105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ferroptosis suppression is RA-dependent or lipid-aldehyde-clearance-dependent not fully resolved\", \"Single study with complex multi-pathway model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The E3 ubiquitin ligase FBXL12 was identified as the specific ubiquitin writer for ALDH1A1 degradation, regulated upstream by sorcin-PAX5 cytoplasmic sequestration; disruption of this axis depletes ALDH1A1 and promotes ferroptosis.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase reporter, FBXL12 overexpression/knockdown, ubiquitylation assay, celastrol functional studies in pancreatic cancer\",\n      \"pmids\": [\"40055736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FBXL12 is the same ligase antagonized by Cdk5 phosphorylation not tested\", \"Sorcin-PAX5-FBXL12 axis validated only in pancreatic cancer\", \"Celastrol target specificity beyond sorcin Cys194 not fully excluded\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions remain: the biochemical mechanism by which ALDH1A1 promotes MMEJ DNA repair, the identity of the metabolite(s) responsible for intracellular pH reduction, how multiple chromatin-regulatory inputs at the ALDH1A1 promoter are hierarchically integrated, and whether ALDH1A1's GABA-synthetic activity in VTA neurons proceeds through a defined substrate.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"MMEJ promotion mechanism (RA-dependent vs direct) unresolved\", \"pH-lowering metabolite identity unknown\", \"Integration of EZH2/ARID1A/DDB2/PBRM1 chromatin regulation hierarchy at ALDH1A1 not tested\", \"GABA synthesis substrate and kinetics not biochemically reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 8, 18, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 5, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 7, 9, 14, 22]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 7, 9, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 12, 13, 20, 30]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 23, 28]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 26]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [24, 28]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CDK5\",\n      \"FBXL12\",\n      \"ZBTB7B\",\n      \"EZH2\",\n      \"ARID1A\",\n      \"DDB2\",\n      \"ARID2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}